Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine

Figure 3

Size distribution profile of immunomodulator product by SEC during stability test at started time (gray line) and after six months (black line). The immunomodulator was produced from (a) volunteer 1, (b) volunteer 2, and (c) volunteer 3.

(a)

(b)

(c)